Vontobel Holding
JNCE

Vontobel Holding’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Vontobel Holding’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$22.2K – 1167
2022
Q4 		$22.2K Buy
+20,000
New +$28.5K ﹤0.01% 1077

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Vontobel Holding's JNCE Position: Q1 2023 in Review

Vontobel Holding sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 20,000 shares — an estimated $22.2K sold.

Vontobel Holding first reported a position in JNCE in Q4 2022 and held it in 1 quarter. The position peaked at $22.2K in Q4 2022. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Vontobel Holding reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vontobel Holding sold 20,000 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $22.2K.
  • Vontobel Holding first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Vontobel Holding's Jounce Therapeutics, Inc. Common Stock position peaked at $22.2K in Q4 2022.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Vontobel Holding's 13F filing for Q1 2023, filed 12 Apr 2023.